spacer
spacer

PDBsum entry 2r5p

Go to PDB code: 
protein ligands metals Protein-protein interface(s) links
Hydrolase PDB id
2r5p

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
99 a.a. *
Ligands
MK1 ×2
Metals
_CL ×4
_NA
Waters ×169
* Residue conservation analysis
PDB id:
2r5p
Name: Hydrolase
Title: Crystal structure analysis of HIV-1 subtypE C protease complexed with indinavir
Structure: Protease. Chain: a, b, c, d. Engineered: yes. Mutation: yes
Source: Human immunodeficiency virus 1. Organism_taxid: 11676. Strain: subtypE C. Gene: pol. Expressed in: escherichia coli. Expression_system_taxid: 562.
Resolution:
2.30Å     R-factor:   0.212     R-free:   0.238
Authors: R.M.Coman,A.H.Robbins,R.Mckenna,B.M.Dunn
Key ref: R.M.Coman et al. (2008). The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease. Biochemistry, 47, 731-743. PubMed id: 18092815
Date:
04-Sep-07     Release date:   20-Nov-07    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chains
Pfam   ArchSchema ?
O12158  (POL_HV192) -  Gag-Pol polyprotein from Human immunodeficiency virus type 1 group M subtype C (isolate 92BR025)
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
1431 a.a.
99 a.a.*
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 7 residue positions (black crosses)

 Enzyme reactions 
   Enzyme class 1: E.C.2.7.7.-  - ?????
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 2: E.C.2.7.7.49  - RNA-directed Dna polymerase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
DNA(n)
+ 2'-deoxyribonucleoside 5'-triphosphate
= DNA(n+1)
+ diphosphate
   Enzyme class 3: E.C.2.7.7.7  - DNA-directed Dna polymerase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
DNA(n)
+ 2'-deoxyribonucleoside 5'-triphosphate
= DNA(n+1)
+ diphosphate
   Enzyme class 4: E.C.3.1.-.-
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 5: E.C.3.1.13.2  - exoribonuclease H.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: Exonucleolytic cleavage to 5'-phosphomonoester oligonucleotides in both 5'- to 3'- and 3'- to 5'-directions.
   Enzyme class 6: E.C.3.1.26.13  - retroviral ribonuclease H.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 7: E.C.3.4.23.16  - HIV-1 retropepsin.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: Specific for a P1 residue that is hydrophobic, and P1' variable, but often Pro.
Note, where more than one E.C. class is given (as above), each may correspond to a different protein domain or, in the case of polyprotein precursors, to a different mature protein.
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    reference    
 
 
Biochemistry 47:731-743 (2008)
PubMed id: 18092815  
 
 
The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease.
R.M.Coman, A.H.Robbins, M.A.Fernandez, C.T.Gilliland, A.A.Sochet, M.M.Goodenow, R.McKenna, B.M.Dunn.
 
  ABSTRACT  
 
Fourteen subtype B and C protease variants have been engineered in an effort to study whether the preexistent baseline polymorphisms, by themselves or in combination with drug resistance mutations, differentially alter the biochemical and structural features of the subtype C protease when compared with those of subtype B protease. The kinetic studies performed in this work showed that the preexistent polymorphisms in subtype C protease, by themselves, do not provide for a greater level of resistance. Inhibition analysis with eight clinically used protease inhibitors revealed that the natural polymorphisms found in subtype C protease, in combination with drug resistance mutations, can influence enzymatic catalytic efficiency and inhibitor resistance. Structural analyses of the subtype C protease bound to nelfinavir and indinavir showed that these inhibitors form similar interactions with the residues in the active site of subtype B and C proteases. It also revealed that the naturally occurring polymorphisms could alter the position of the outer loops of the subtype C protease, especially the 60's loop.
 

Literature references that cite this PDB file's key reference

  PubMed id Reference
20964479 B.Chaplin, G.Eisen, J.Idoko, D.Onwujekwe, E.Idigbe, I.Adewole, W.Gashau, S.Meloni, A.D.Sarr, J.L.Sankalé, E.Ekong, R.L.Murphy, and P.Kanki (2011).
Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.
  AIDS Res Hum Retroviruses, 27, 71-80.  
20179334 A.H.Robbins, R.M.Coman, E.Bracho-Sanchez, M.A.Fernandez, C.T.Gilliland, M.Li, M.Agbandje-McKenna, A.Wlodawer, B.M.Dunn, and R.McKenna (2010).
Structure of the unbound form of HIV-1 subtype A protease: comparison with unbound forms of proteases from other HIV subtypes.
  Acta Crystallogr D Biol Crystallogr, 66, 233-242.
PDB code: 3ixo
20737578 J.M.Sayer, J.Agniswamy, I.T.Weber, and J.M.Louis (2010).
Autocatalytic maturation, physical/chemical properties, and crystal structure of group N HIV-1 protease: relevance to drug resistance.
  Protein Sci, 19, 2055-2072.
PDB code: 3mws
20623996 S.Gonzalez, C.Gondwe, D.C.Tully, V.Minhas, D.Shea, C.Kankasa, T.M'soka, and C.Wood (2010).
Short communication: antiretroviral therapy resistance mutations present in the HIV type 1 subtype C pol and env regions from therapy-naive patients in Zambia.
  AIDS Res Hum Retroviruses, 26, 795-803.  
  20978602 S.Shityakov, and T.Dandekar (2010).
Lead expansion and virtual screening of Indinavir derivate HIV-1 protease inhibitors using pharmacophoric - shape similarity scoring function.
  Bioinformation, 4, 295-299.  
19788299 J.L.Kear, M.E.Blackburn, A.M.Veloro, B.M.Dunn, and G.E.Fanucci (2009).
Subtype polymorphisms among HIV-1 protease variants confer altered flap conformations and flexibility.
  J Am Chem Soc, 131, 14650-14651.  
19625947 S.K.Ho, E.E.Perez, S.L.Rose, R.M.Coman, A.C.Lowe, W.Hou, C.Ma, R.M.Lawrence, B.M.Dunn, J.W.Sleasman, and M.M.Goodenow (2009).
Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.
  AIDS, 23, 1631-1640.  
18597780 F.Liu, A.Y.Kovalevsky, Y.Tie, A.K.Ghosh, R.W.Harrison, and I.T.Weber (2008).
Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.
  J Mol Biol, 381, 102-115.
PDB codes: 3cyw 3cyx 3d1x 3d1y 3d1z 3d20
18768960 S.Mosebi, L.Morris, H.W.Dirr, and Y.Sayed (2008).
Active-site mutations in the South african human immunodeficiency virus type 1 subtype C protease have a significant impact on clinical inhibitor binding: kinetic and thermodynamic study.
  J Virol, 82, 11476-11479.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB code is shown on the right.

 

spacer

spacer